New initiative aims to shorten timelines from early-stage research to late-stage clinical trials through regulatory reforms.

The FDA and the NIH are streamlining clinical trial research guidelines to bolster U.S. biotech, calling it "Operation Trial Blazer."

Federal health officials aim to speed up drug development and better compete with China.